AU6584401A - A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease - Google Patents
A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's diseaseInfo
- Publication number
- AU6584401A AU6584401A AU6584401A AU6584401A AU6584401A AU 6584401 A AU6584401 A AU 6584401A AU 6584401 A AU6584401 A AU 6584401A AU 6584401 A AU6584401 A AU 6584401A AU 6584401 A AU6584401 A AU 6584401A
- Authority
- AU
- Australia
- Prior art keywords
- galantamine
- alzheimer
- disease
- treatment
- behaviour associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 | |
| PCT/EP2001/003553 WO2001074339A2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU6584401A true AU6584401A (en) | 2001-10-15 |
Family
ID=22716898
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU6584401A Pending AU6584401A (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| AU2001265844A Ceased AU2001265844B2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001265844A Ceased AU2001265844B2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (xx) |
| JP (1) | JP2003528913A (xx) |
| KR (1) | KR20020086911A (xx) |
| CN (1) | CN1430514A (xx) |
| AU (2) | AU6584401A (xx) |
| BG (1) | BG107093A (xx) |
| BR (1) | BR0109770A (xx) |
| CA (1) | CA2310926C (xx) |
| CZ (1) | CZ20023543A3 (xx) |
| EE (1) | EE200200554A (xx) |
| HR (1) | HRP20020778A2 (xx) |
| HU (1) | HUP0300566A3 (xx) |
| IL (1) | IL152061A0 (xx) |
| MX (1) | MXPA02009777A (xx) |
| NO (1) | NO20024746L (xx) |
| PL (1) | PL361272A1 (xx) |
| RU (1) | RU2002129298A (xx) |
| SK (1) | SK15422002A3 (xx) |
| WO (1) | WO2001074339A2 (xx) |
| ZA (1) | ZA200207935B (xx) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| EP1651234B1 (en) | 2003-07-25 | 2007-09-26 | F. Hoffmann-La Roche Ag | Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| AU2009229372C1 (en) | 2008-03-27 | 2017-02-02 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| WO2016187339A1 (en) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | GALANTAMINE CLEARANCE OF AMYLOIDß |
| CN117957003A (zh) * | 2021-09-09 | 2024-04-30 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| AU1738800A (en) | 1998-11-23 | 2000-06-13 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| ES2211215T3 (es) * | 1998-12-24 | 2004-07-01 | Janssen Pharmaceutica N.V. | Composicion de galantamina de liberacion controlada. |
| CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Application Discontinuation
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Application Discontinuation
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EE200200554A (et) | 2004-04-15 |
| CA2310926A1 (en) | 2000-10-04 |
| PL361272A1 (en) | 2004-10-04 |
| AU2001265844B2 (en) | 2005-04-14 |
| BR0109770A (pt) | 2003-02-04 |
| SK15422002A3 (sk) | 2003-04-01 |
| HUP0300566A3 (en) | 2004-10-28 |
| ZA200207935B (en) | 2004-01-30 |
| MXPA02009777A (es) | 2003-03-27 |
| CZ20023543A3 (cs) | 2003-03-12 |
| BG107093A (bg) | 2003-06-30 |
| IL152061A0 (en) | 2003-05-29 |
| HUP0300566A2 (hu) | 2003-06-28 |
| CN1430514A (zh) | 2003-07-16 |
| EP1272192A2 (en) | 2003-01-08 |
| CA2310926C (en) | 2002-10-15 |
| WO2001074339A3 (en) | 2002-09-12 |
| KR20020086911A (ko) | 2002-11-20 |
| WO2001074339A2 (en) | 2001-10-11 |
| NO20024746L (no) | 2002-11-28 |
| RU2002129298A (ru) | 2004-03-27 |
| JP2003528913A (ja) | 2003-09-30 |
| HRP20020778A2 (en) | 2004-04-30 |
| NO20024746D0 (no) | 2002-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL153214A0 (en) | Compounds to treat alzheimer's disease | |
| PT2264018E (pt) | Derivados de tioflavina para uso no diagnóstico da doença de alzheimer | |
| EP1043991A4 (en) | TREATMENT OF ALZHEIMER DISEASE | |
| AU2001273132A1 (en) | Compounds to treat alzheimer's disease | |
| HUP0103838A3 (en) | Alzheimer's disease secretase | |
| AU2001233299A1 (en) | Methods for treating alzheimer's disease | |
| SI1303272T1 (sl) | Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni | |
| AU2001278084A1 (en) | Model for alzheimer's disease and other neurodegenerative diseases | |
| EP1007048A4 (en) | IDENTIFICATION OF AGENTS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | |
| IL155191A0 (en) | Radiopharmaceuticals for diagnosing alzheimer's disease | |
| AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| NO20001869D0 (no) | Fremgangsmõte for behandling av Alzheimerssykdom | |
| AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
| AU2001236592A1 (en) | Methods for diagnosis of alzheimer's disease | |
| HUP0300566A3 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| HUP9903213A3 (en) | Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producing a pharmaceutical preparation intended for treatment of the alzheimer's disease | |
| GB0011410D0 (en) | Therapeutic combination for treating Alzheimer's disease | |
| ZA962715B (en) | Pharmaceutical agents for the treatment of Alzheimer's disease. | |
| GB0011408D0 (en) | Therapeutic combination for treating Alzheimer's Disease | |
| AU2001248760A1 (en) | Preventives/remedies for alzheimer's disease | |
| EP1181550A4 (en) | METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| AU2001246518A1 (en) | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease | |
| AU2001267826A1 (en) | Remedies for alzheimer's disease | |
| AU2002364885A8 (en) | Alzheimer's disease model |